AKBA FY 2022 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$292M+38.2% YoY

Gross Profit

$270M92.3% margin

Operating Income

-$81M-27.6% margin

Net Income

-$94M-32.2% margin

EPS (Diluted)

$-0.58

Cash Flow

Operating Cash Flow

-$73M

Free Cash Flow

-$73M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$356M

Total Liabilities

$351M

Stockholders' Equity

$5M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$292M	$212M	+38.2%
Gross Profit	$270M	$130M	+107.4%
Operating Income	-$81M	-$265M	+69.5%
Net Income	-$94M	-$282M	+66.6%